Brahma‑related gene 1-associated expression of 9-27 and IFI-27 is involved in acquired cisplatin resistance of gastric cancer cells

Lee,Hye  Ran; No,Hyun   Kyung; Ryu,Chun  Jeih; Park,Hyun-Ju

doi:10.3892/mmr.2013.1576

Brahma‑related gene 1-associated expression of 9-27 and IFI-27 is involved in acquired cisplatin resistance of gastric cancer cells

Authors:
- Hye Ran Lee
- Hyun Kyung No
- Chun Jeih Ryu
- Hyun-Ju Park
View Affiliations

Affiliations: Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Gyeonggi-do 411-706, Republic of Korea, School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do 440-746, Republic of Korea, Department of Bioscience and Biotechnology, Sejong University, Kwanjin-Gu, Seoul 143-747, Republic of Korea
Published online on: July 8, 2013 https://doi.org/10.3892/mmr.2013.1576
Pages: 747-750

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In order to investigate the mechanism of cisplatin resistance, a cisplatin‑resistant human gastric cancer cell line was established. Subsequent to the exposure of the YCC-3 gastric cancer cell line to equal concentrations of cis‑diammine‑dichloroplatinum (II) (cisplatin, CDDP) for 6 months, a cisplatin-resistant cell line was established (YCC‑3/R). To determine the molecular mechanism of cisplatin resistance in YCC‑3/R cells, differentially expressed genes (DEGs) were investigated between YCC‑3 and YCC-3/R by annealing control primer-based reverse transcriptase-polymerase chain reaction (ACP RT‑PCR) technology. Eleven DEGs were successfully identified and sequenced. Among them, interferon‑induced transmembrane protein 1 (9‑27) and interferon α‑inducible protein 27 (IFI‑27) were markedly increased in YCC‑3/R cells. In addition, western blot analysis demonstrated that the Brahma‑related gene 1 (BRG1), which was observed to selectively activate 9‑27 and IFI‑27 genes, was overexpressed in YCC‑3/R cells. The results suggested that the BRG1‑associated expression of 9‑27 and IFI‑27 is involved in cisplatin resistance in gastric cancer cells.

View Figures

View References

1	Kelley JR and Duggan JM: Gastric cancer epidemiology and risk factors. J Clin Epidemiol. 56:1–9. 2003. View Article : Google Scholar : PubMed/NCBI
2	Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R and Bertino JR: Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta. 1587:164–173. 2002. View Article : Google Scholar : PubMed/NCBI
3	Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
4	Larsen AK, Escargueil AE and Skladanowski A: Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther. 85:217–229. 2000. View Article : Google Scholar : PubMed/NCBI
5	Fuertes MA, Alonso C and Pérez JM: Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev. 103:645–662. 2003. View Article : Google Scholar : PubMed/NCBI
6	Konishi H, Usui T, Sawada H, Uchino H and Kidani Y: Effects of anticancer platinum compounds on Escherichia coli strains with normal and defective DNA repair capacity. Gann. 72:627–630. 1981.PubMed/NCBI
7	Beck DJ, Popoff S, Sancar A and Rupp WD: Reactions of the UVRABC excision nuclease with DNA damaged by diamminedichloroplatinum(II). Nucleic Acids Res. 13:7395–7412. 1985. View Article : Google Scholar : PubMed/NCBI
8	Fram RJ, Cusick PS and Marinus MG: Studies on mutagenesis and repair induced by platinum analogs. Mutat Res. 173:13–18. 1986. View Article : Google Scholar : PubMed/NCBI
9	Kartalou M and Essigmann JM: Mechanisms of resistance to cisplatin. Mutat Res. 478:23–43. 2001. View Article : Google Scholar : PubMed/NCBI
10	Brown R, Hirst GL, Gallagher WM, et al: hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene. 15:45–52. 1997. View Article : Google Scholar : PubMed/NCBI
11	Fink D, Nebel S, Aebi S, et al: The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 56:4881–4886. 1996.PubMed/NCBI
12	Vaisman A, Varchenko M, Umar A, et al: The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res. 58:3579–3585. 1998.PubMed/NCBI
13	Kim YJ, Kwak CI, Gu YY, Hwang IT and Chun JY: Annealing control primer system for identification of differentially expressed genes on agarose gels. Biotechniques. 36:424–426. 2004.PubMed/NCBI
14	Hwang KC, Cui XS, Park SP, et al: Identification of differentially regulated genes in bovine blastocysts using an annealing control primer system. Mol Reprod Dev. 69:43–51. 2004. View Article : Google Scholar : PubMed/NCBI
15	Lee KY, Huang SM, Li S and Kim JM: Identification of differentially expressed genes in papillary thyroid cancers. Yonsei Med J. 50:60–67. 2009. View Article : Google Scholar : PubMed/NCBI
16	Le TV, Seo Y, Ryu CJ, Lee HR and Park HJ: Increased expression of p27 is associated with the cisplatin resistance in gastric cancer cell line YCC-3. Arch Pharm Res. 33:1127–1132. 2010. View Article : Google Scholar : PubMed/NCBI
17	Altschul SF, Gish W, Miller W, Myers EW and Lipman DJ: Basic local alignment search tool. J Mol Biol. 215:403–410. 1990. View Article : Google Scholar
18	Yoon IS, Chung JH, Hahm SH, et al: Ribosomal protein S3 is phosphorylated by Cdk1/cdc2 during G2/M phase. BMB Rep. 44:529–534. 2011. View Article : Google Scholar : PubMed/NCBI
19	Huang M, Qian F, Hu Y, Ang C, Li Z and Wen Z: Chromatin-remodelling factor BRG1 selectively activates a subset of interferon-alpha-inducible genes. Nat Cell Biol. 4:774–781. 2002. View Article : Google Scholar : PubMed/NCBI
20	Deblandre GA, Marinx OP, Evans SS, et al: Expression cloning of an interferon-inducible 17-kDa membrane protein implicated in the control of cell growth. J Biol Chem. 270:23860–23866. 1995. View Article : Google Scholar : PubMed/NCBI
21	Kang HC, Kim IJ, Park JH, et al: Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res. 10:272–284. 2004. View Article : Google Scholar : PubMed/NCBI
22	Luker KE, Pica CM, Schreiber RD and Piwnica-Worms D: Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells. Cancer Res. 61:6540–6547. 2001.PubMed/NCBI
23	Yang G, Xu Y, Chen X and Hu G: IFITM1 plays an essential role in the antiproliferative action of interferon-gamma. Oncogene. 26:594–603. 2007. View Article : Google Scholar : PubMed/NCBI
24	Sentani K, Oue N, Kondo H, et al: Increased expression but not genetic alteration of BRG1, a component of the SWI/SNF complex, is associated with the advanced stage of human gastric carcinomas. Pathobiology. 69:315–320. 2001. View Article : Google Scholar : PubMed/NCBI
25	Kothandapani A, Gopalakrishnan K, Kahali B, Reisman D and Patrick SM: Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity. Exp Cell Res. 318:1973–1986. 2012. View Article : Google Scholar : PubMed/NCBI